Polypharmacy and Bleeding Outcomes After Percutaneous Coronary Intervention
Background: Polypharmacy was reported to be associated with major bleeding in various populations. However, there are no data on polypharmacy and its association with bleeding in patients undergoing percutaneous coronary intervention (PCI).Methods and Results: Among 12,291 patients in the CREDO-Kyot...
Saved in:
| Published in | Circulation Journal Vol. 88; no. 6; pp. 888 - 899 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
The Japanese Circulation Society
24.05.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1346-9843 1347-4820 1347-4820 |
| DOI | 10.1253/circj.CJ-23-0558 |
Cover
| Abstract | Background: Polypharmacy was reported to be associated with major bleeding in various populations. However, there are no data on polypharmacy and its association with bleeding in patients undergoing percutaneous coronary intervention (PCI).Methods and Results: Among 12,291 patients in the CREDO-Kyoto PCI Registry Cohort-3, we evaluated the number of medications at discharge and compared major bleeding, defined as Bleeding Academic Research Consortium Type 3 or 5 bleeding, across tertiles (T1–3) of the number of medications. The median number of medications was 6, and 88.0% of patients were on ≥5 medications. The cumulative 5-year incidence of major bleeding increased incrementally with increasing number of medications (T1 [≤5 medications] 12.5%, T2 [6–7] 16.5%, and T3 [≥8] 20.4%; log-rank P<0.001). After adjusting for confounders, the risks for major bleeding of T2 (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.08–1.36; P=0.001) and T3 (HR 1.27; 95% CI 1.12–1.45; P<0.001) relative to T1 remained significant. The adjusted risks of T2 and T3 relative to T1 were not significant for a composite of myocardial infarction or ischemic stroke (HR 0.95 [95% CI 0.83–1.09; P=0.47] and HR 1.06 [95% CI 0.91–1.23; P=0.48], respectively).Conclusions: In a real-world population of patients undergoing PCI, approximately 90% were on ≥5 medications. Increasing number of medications was associated with a higher adjusted risk for major bleeding, but not ischemic events. |
|---|---|
| AbstractList | Polypharmacy was reported to be associated with major bleeding in various populations. However, there are no data on polypharmacy and its association with bleeding in patients undergoing percutaneous coronary intervention (PCI).BACKGROUNDPolypharmacy was reported to be associated with major bleeding in various populations. However, there are no data on polypharmacy and its association with bleeding in patients undergoing percutaneous coronary intervention (PCI).Among 12,291 patients in the CREDO-Kyoto PCI Registry Cohort-3, we evaluated the number of medications at discharge and compared major bleeding, defined as Bleeding Academic Research Consortium Type 3 or 5 bleeding, across tertiles (T1-3) of the number of medications. The median number of medications was 6, and 88.0% of patients were on ≥5 medications. The cumulative 5-year incidence of major bleeding increased incrementally with increasing number of medications (T1 [≤5 medications] 12.5%, T2 [6-7] 16.5%, and T3 [≥8] 20.4%; log-rank P<0.001). After adjusting for confounders, the risks for major bleeding of T2 (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.08-1.36; P=0.001) and T3 (HR 1.27; 95% CI 1.12-1.45; P<0.001) relative to T1 remained significant. The adjusted risks of T2 and T3 relative to T1 were not significant for a composite of myocardial infarction or ischemic stroke (HR 0.95 [95% CI 0.83-1.09; P=0.47] and HR 1.06 [95% CI 0.91-1.23; P=0.48], respectively).METHODS AND RESULTSAmong 12,291 patients in the CREDO-Kyoto PCI Registry Cohort-3, we evaluated the number of medications at discharge and compared major bleeding, defined as Bleeding Academic Research Consortium Type 3 or 5 bleeding, across tertiles (T1-3) of the number of medications. The median number of medications was 6, and 88.0% of patients were on ≥5 medications. The cumulative 5-year incidence of major bleeding increased incrementally with increasing number of medications (T1 [≤5 medications] 12.5%, T2 [6-7] 16.5%, and T3 [≥8] 20.4%; log-rank P<0.001). After adjusting for confounders, the risks for major bleeding of T2 (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.08-1.36; P=0.001) and T3 (HR 1.27; 95% CI 1.12-1.45; P<0.001) relative to T1 remained significant. The adjusted risks of T2 and T3 relative to T1 were not significant for a composite of myocardial infarction or ischemic stroke (HR 0.95 [95% CI 0.83-1.09; P=0.47] and HR 1.06 [95% CI 0.91-1.23; P=0.48], respectively).In a real-world population of patients undergoing PCI, approximately 90% were on ≥5 medications. Increasing number of medications was associated with a higher adjusted risk for major bleeding, but not ischemic events.CONCLUSIONSIn a real-world population of patients undergoing PCI, approximately 90% were on ≥5 medications. Increasing number of medications was associated with a higher adjusted risk for major bleeding, but not ischemic events. Background: Polypharmacy was reported to be associated with major bleeding in various populations. However, there are no data on polypharmacy and its association with bleeding in patients undergoing percutaneous coronary intervention (PCI).Methods and Results: Among 12,291 patients in the CREDO-Kyoto PCI Registry Cohort-3, we evaluated the number of medications at discharge and compared major bleeding, defined as Bleeding Academic Research Consortium Type 3 or 5 bleeding, across tertiles (T1–3) of the number of medications. The median number of medications was 6, and 88.0% of patients were on ≥5 medications. The cumulative 5-year incidence of major bleeding increased incrementally with increasing number of medications (T1 [≤5 medications] 12.5%, T2 [6–7] 16.5%, and T3 [≥8] 20.4%; log-rank P<0.001). After adjusting for confounders, the risks for major bleeding of T2 (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.08–1.36; P=0.001) and T3 (HR 1.27; 95% CI 1.12–1.45; P<0.001) relative to T1 remained significant. The adjusted risks of T2 and T3 relative to T1 were not significant for a composite of myocardial infarction or ischemic stroke (HR 0.95 [95% CI 0.83–1.09; P=0.47] and HR 1.06 [95% CI 0.91–1.23; P=0.48], respectively).Conclusions: In a real-world population of patients undergoing PCI, approximately 90% were on ≥5 medications. Increasing number of medications was associated with a higher adjusted risk for major bleeding, but not ischemic events. Polypharmacy was reported to be associated with major bleeding in various populations. However, there are no data on polypharmacy and its association with bleeding in patients undergoing percutaneous coronary intervention (PCI). Among 12,291 patients in the CREDO-Kyoto PCI Registry Cohort-3, we evaluated the number of medications at discharge and compared major bleeding, defined as Bleeding Academic Research Consortium Type 3 or 5 bleeding, across tertiles (T1-3) of the number of medications. The median number of medications was 6, and 88.0% of patients were on ≥5 medications. The cumulative 5-year incidence of major bleeding increased incrementally with increasing number of medications (T1 [≤5 medications] 12.5%, T2 [6-7] 16.5%, and T3 [≥8] 20.4%; log-rank P<0.001). After adjusting for confounders, the risks for major bleeding of T2 (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.08-1.36; P=0.001) and T3 (HR 1.27; 95% CI 1.12-1.45; P<0.001) relative to T1 remained significant. The adjusted risks of T2 and T3 relative to T1 were not significant for a composite of myocardial infarction or ischemic stroke (HR 0.95 [95% CI 0.83-1.09; P=0.47] and HR 1.06 [95% CI 0.91-1.23; P=0.48], respectively). In a real-world population of patients undergoing PCI, approximately 90% were on ≥5 medications. Increasing number of medications was associated with a higher adjusted risk for major bleeding, but not ischemic events. |
| ArticleNumber | CJ-23-0558 |
| Author | Natsuaki, Masahiro Eizawa, Hiroshi Ozasa, Neiko Taniguchi, Ryoji Kadota, Kazushige Onodera, Tomoya Sakamoto, Hiroki Inoko, Moriaki Furukawa, Yutaka on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators Takeda, Teruki Inada, Tsukasa Ishii, Katsuhisa Domei, Takenori Ando, Kenji Uegaito, Takashi Toyofuku, Mamoru Takeji, Yasuaki Yamamoto, Ko Nakagawa, Yoshihisa Tada, Takeshi Miki, Shinji Shiomi, Hiroki Suwa, Satoru Kimura, Takeshi Morimoto, Takeshi Sakai, Hiroshi Tamura, Toshihiro Yamada, Miho Shirotani, Manabu |
| Author_xml | – sequence: 1 fullname: Tada, Takeshi organization: Department of Cardiology, Kurashiki Central Hospital – sequence: 1 fullname: Kimura, Takeshi organization: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine – sequence: 1 fullname: Morimoto, Takeshi organization: Department of Clinical Epidemiology, Hyogo College of Medicine – sequence: 1 fullname: Kadota, Kazushige organization: Department of Cardiology, Kurashiki Central Hospital – sequence: 1 fullname: Ishii, Katsuhisa organization: Department of Cardiology, Kansai Electric Power Hospital – sequence: 1 fullname: Onodera, Tomoya organization: Department of Cardiology, Shizuoka City Shizuoka Hospital – sequence: 1 fullname: Domei, Takenori organization: Department of Cardiology, Kokura Memorial Hospital – sequence: 1 fullname: Sakai, Hiroshi organization: Department of Cardiovascular Medicine, Shiga University of Medical Science – sequence: 1 fullname: Inada, Tsukasa organization: Department of Cardiovascular Center, Osaka Red Cross Hospital – sequence: 1 fullname: Natsuaki, Masahiro organization: Department of Cardiovascular Medicine, Saga University – sequence: 1 fullname: Furukawa, Yutaka organization: Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital – sequence: 1 fullname: Shirotani, Manabu organization: Department of Cardiology, Kindai University Nara Hospital – sequence: 1 fullname: Suwa, Satoru organization: Department of Cardiology, Juntendo University Shizuoka Hospital – sequence: 1 fullname: Yamamoto, Ko organization: Department of Cardiology, Kokura Memorial Hospital – sequence: 1 fullname: Taniguchi, Ryoji organization: Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center – sequence: 1 fullname: Tamura, Toshihiro organization: Department of Cardiovascular Surgery, Tenri Hospital – sequence: 1 fullname: Miki, Shinji organization: Department of Cardiology, Mitsubishi Kyoto Hospital – sequence: 1 fullname: Shiomi, Hiroki organization: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine – sequence: 1 fullname: Eizawa, Hiroshi organization: Department of Cardiology, Kobe City Nishi-Kobe Medical Center – sequence: 1 fullname: Toyofuku, Mamoru organization: Department of Cardiology, Japanese Red Cross Wakayama Medical Center – sequence: 1 fullname: on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators – sequence: 1 fullname: Takeji, Yasuaki organization: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine – sequence: 1 fullname: Uegaito, Takashi organization: Department of Cardiology, Kishiwada City Hospital – sequence: 1 fullname: Ando, Kenji organization: Department of Cardiology, Kokura Memorial Hospital – sequence: 1 fullname: Sakamoto, Hiroki organization: Department of Cardiology, Shizuoka General Hospital – sequence: 1 fullname: Yamada, Miho organization: Department of Cardiology, Hamamatsu Rosai Hospital – sequence: 1 fullname: Takeda, Teruki organization: Department of Cardiology, Koto Memorial Hospital – sequence: 1 fullname: Inoko, Moriaki organization: Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital – sequence: 1 fullname: Nakagawa, Yoshihisa organization: Department of Cardiovascular Medicine, Shiga University of Medical Science – sequence: 1 fullname: Ozasa, Neiko organization: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37722886$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctP3DAQh60KVB7tvacqx14CfmXsHGlUWh4SHOBsOc6EZpXYW9tB2v--WXYBqYdePJb8faPxb07IgQ8eCfnC6BnjlTh3Q3Srs-a65KKkVaU_kGMmpCql5vTg5Q5lraU4IicprSjlNa3qj-RIKMW51nBMbu7DuFn_tnGyblNY3xXfR8Ru8E_F3ZxdmDAVF33GWNxjdHO2HsOciibE4G3cFFd-eXtGn4fgP5HD3o4JP-_rKXm8_PHQ_Cpv735eNRe3pQOQuWwZF5RJJSnQqsWeonIdKK1VJznreS257aVoodagpeoqwUADU5wCtKzj4pR82_Vdx_BnxpTNNCSH47gbznANIFQNFVvQr3t0bifszDoO0zK2eQ1gAWAHuBhSitgbN2S7_U2OdhgNo2abtHlJ2jTXhguzTXoR6T_ia-__KJc7ZZWyfcI3wcY8uBH3gtYGtse7-A4sezLoxV8GY5pY |
| CitedBy_id | crossref_primary_10_1253_circj_CJ_23_0720 crossref_primary_10_1253_circrep_CR_24_0141 crossref_primary_10_1007_s12928_024_01022_4 |
| Cites_doi | 10.1161/CIRCULATIONAHA.122.061527 10.1007/s11606-014-2993-8 10.1016/j.amjcard.2021.08.013 10.1161/CIRCULATIONAHA.115.018544 10.1093/ageing/afu141 10.1111/j.1447-0594.2011.00783.x 10.1186/1472-6904-10-16 10.1161/CIRCULATIONAHA.106.685313 10.1016/j.amjcard.2020.12.078 10.1046/j.1525-1497.1998.00053.x 10.1016/j.amjcard.2020.12.076 10.1161/CIRCULATIONAHA.110.009449 10.1016/j.jamda.2017.12.013 10.1007/s41999-019-00162-8 10.1002/jcph.2106 10.1136/bmj.i2868 10.1111/jth.15692 10.1001/jama.275.11.852 10.1007/s11606-010-1518-3 |
| ContentType | Journal Article |
| Copyright | 2024, THE JAPANESE CIRCULATION SOCIETY |
| Copyright_xml | – notice: 2024, THE JAPANESE CIRCULATION SOCIETY |
| CorporateAuthor | on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators |
| CorporateAuthor_xml | – name: on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators – name: CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1253/circj.CJ-23-0558 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1347-4820 |
| EndPage | 899 |
| ExternalDocumentID | 37722886 10_1253_circj_CJ_23_0558 article_circj_88_6_88_CJ_23_0558_article_char_en |
| Genre | Multicenter Study Research Support, Non-U.S. Gov't Journal Article Observational Study |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- .55 29B 2WC 53G 5GY 5RE 6J9 ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P GX1 JSF JSH KQ8 OK1 OVT P2P RJT RNS RZJ TR2 W2D X7M XSB ZXP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c664t-b123014740605bef0e7cd67887d421f2942af43b6986847d531686172066b1d23 |
| ISSN | 1346-9843 1347-4820 |
| IngestDate | Fri Jul 11 03:26:35 EDT 2025 Sat Sep 06 06:29:47 EDT 2025 Tue Jul 01 02:01:35 EDT 2025 Thu Apr 24 22:51:16 EDT 2025 Wed Sep 03 06:30:23 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Percutaneous coronary intervention Polypharmacy Coronary stent Bleeding |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc-nd/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c664t-b123014740605bef0e7cd67887d421f2942af43b6986847d531686172066b1d23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/circj/88/6/88_CJ-23-0558/_article/-char/en |
| PMID | 37722886 |
| PQID | 2866379651 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2866379651 pubmed_primary_37722886 crossref_citationtrail_10_1253_circj_CJ_23_0558 crossref_primary_10_1253_circj_CJ_23_0558 jstage_primary_article_circj_88_6_88_CJ_23_0558_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-24 |
| PublicationDateYYYYMMDD | 2024-05-24 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-24 day: 24 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Circulation Journal |
| PublicationTitleAlternate | Circ J |
| PublicationYear | 2024 |
| Publisher | The Japanese Circulation Society |
| Publisher_xml | – name: The Japanese Circulation Society |
| References | 7. Bistervels IM, Bavalia R, Gebel M, Lensing AWA, Middeldorp S, Prins MH, et al. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. J Thromb Haemost 2022; 20: 1376–1384. 8. Leiss W, Méan M, Limacher A, Righini M, Jaeger K, Beer HJ, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med 2015; 30: 17–24. 12. Yamamoto K, Shiomi H, Morimoto T, Kadota K, Tada T, Takeji Y, et al. percutaneous coronary intervention versus coronary artery bypass grafting among patients with unprotected left main coronary artery disease in the new-generation drug-eluting stents era (from the CREDO-Kyoto PCI/CABG Registry Cohort-3). Am J Cardiol 2021; 145: 47–57. 3. Fincke BG, Miller DR, Spiro A 3rd. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med 1998; 13: 182–185. 1. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy: An individual-based study of the Swedish population 2005–2008. BMC Clin Pharmacol 2010; 10: 16. 22. Gargiulo G, Giacoppo D, Jolly SS, Cairns J, Le May M, Bernat I, et al. Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: Meta-analysis of individual patient data from 7 multicenter randomized clinical trials. Circulation 2022; 146: 1329–1343. 2. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM; HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890–1896. 16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344–2351. 14. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. 2023. https://www.whocc.no/atc_ddd_index/ (accessed August 31, 2023). 21. Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, Iijima K, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 2012; 12: 425–430. 5. Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 2016; 133: 352–360. 4. Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons: Predictive model and interrelationship with baseline vulnerability. JAMA 1996; 275: 852–857. 20. Richardson K, Bennett K, Kenny RA. Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age Ageing 2015; 44: 90–96. 6. Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial. BMJ 2016; 353: i2868. 13. Yamamoto K, Natsuaki M, Morimoto T, Shiomi H, Ozasa N, Sakamoto H, et al. Effect of polypharmacy on long-term mortality after percutaneous coronary intervention. Am J Cardiol 2021; 159: 19–29. 15. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736–2747. 17. Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: The JADE study. J Gen Intern Med 2011; 26: 148–153. 18. Seppala LJ, van der Velde N, Masud T, Blain H, Petrovic M, van der Cammen TJ, et al. EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs (FRIDs): Position on knowledge dissemination, management, and future research. Eur Geriatr Med 2019; 10: 275–283. 10. US Food and Drug Administration (FDA). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020839 (accessed December 29, 2022). 11. Matsumura-Nakano Y, Shiomi H, Morimoto T, Yamaji K, Ehara N, Sakamoto H, et al. Comparison of outcomes of percutaneous coronary intervention versus coronary artery bypass grafting among patients with three-vessel coronary artery disease in the new-generation drug-eluting stents era (from CREDO-Kyoto PCI/CABG Registry Cohort-3). Am J Cardiol 2021; 145: 25–36. 19. de Vries M, Seppala LJ, Daams JG, van de Glind EMM, Masud T, van der Velde N, et al. Fall-risk-increasing drugs: A systematic review and meta-analysis: I. Cardiovascular drugs. J Am Med Dir Assoc 2018; 19: 371.e1–371.e9. 9. Honda T, Abe K, Oda M, Harada F, Maruyama K, Aoyagi H, et al. Gastrointestinal bleeding during direct oral anticoagulant therapy in patients with nonvalvular atrial fibrillation and risk of polypharmacy. J Clin Pharmacol 2022; 62: 1548–1556. 11 22 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 10 21 37914273 - Circ J. 2024 May 24;88(6):900-901. doi: 10.1253/circj.CJ-23-0720. |
| References_xml | – reference: 22. Gargiulo G, Giacoppo D, Jolly SS, Cairns J, Le May M, Bernat I, et al. Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: Meta-analysis of individual patient data from 7 multicenter randomized clinical trials. Circulation 2022; 146: 1329–1343. – reference: 17. Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: The JADE study. J Gen Intern Med 2011; 26: 148–153. – reference: 18. Seppala LJ, van der Velde N, Masud T, Blain H, Petrovic M, van der Cammen TJ, et al. EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs (FRIDs): Position on knowledge dissemination, management, and future research. Eur Geriatr Med 2019; 10: 275–283. – reference: 4. Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons: Predictive model and interrelationship with baseline vulnerability. JAMA 1996; 275: 852–857. – reference: 11. Matsumura-Nakano Y, Shiomi H, Morimoto T, Yamaji K, Ehara N, Sakamoto H, et al. Comparison of outcomes of percutaneous coronary intervention versus coronary artery bypass grafting among patients with three-vessel coronary artery disease in the new-generation drug-eluting stents era (from CREDO-Kyoto PCI/CABG Registry Cohort-3). Am J Cardiol 2021; 145: 25–36. – reference: 5. Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 2016; 133: 352–360. – reference: 14. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. 2023. https://www.whocc.no/atc_ddd_index/ (accessed August 31, 2023). – reference: 15. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736–2747. – reference: 9. Honda T, Abe K, Oda M, Harada F, Maruyama K, Aoyagi H, et al. Gastrointestinal bleeding during direct oral anticoagulant therapy in patients with nonvalvular atrial fibrillation and risk of polypharmacy. J Clin Pharmacol 2022; 62: 1548–1556. – reference: 19. de Vries M, Seppala LJ, Daams JG, van de Glind EMM, Masud T, van der Velde N, et al. Fall-risk-increasing drugs: A systematic review and meta-analysis: I. Cardiovascular drugs. J Am Med Dir Assoc 2018; 19: 371.e1–371.e9. – reference: 6. Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial. BMJ 2016; 353: i2868. – reference: 10. US Food and Drug Administration (FDA). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020839 (accessed December 29, 2022). – reference: 2. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM; HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890–1896. – reference: 8. Leiss W, Méan M, Limacher A, Righini M, Jaeger K, Beer HJ, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med 2015; 30: 17–24. – reference: 20. Richardson K, Bennett K, Kenny RA. Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age Ageing 2015; 44: 90–96. – reference: 16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344–2351. – reference: 12. Yamamoto K, Shiomi H, Morimoto T, Kadota K, Tada T, Takeji Y, et al. percutaneous coronary intervention versus coronary artery bypass grafting among patients with unprotected left main coronary artery disease in the new-generation drug-eluting stents era (from the CREDO-Kyoto PCI/CABG Registry Cohort-3). Am J Cardiol 2021; 145: 47–57. – reference: 3. Fincke BG, Miller DR, Spiro A 3rd. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med 1998; 13: 182–185. – reference: 13. Yamamoto K, Natsuaki M, Morimoto T, Shiomi H, Ozasa N, Sakamoto H, et al. Effect of polypharmacy on long-term mortality after percutaneous coronary intervention. Am J Cardiol 2021; 159: 19–29. – reference: 7. Bistervels IM, Bavalia R, Gebel M, Lensing AWA, Middeldorp S, Prins MH, et al. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. J Thromb Haemost 2022; 20: 1376–1384. – reference: 21. Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, Iijima K, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 2012; 12: 425–430. – reference: 1. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy: An individual-based study of the Swedish population 2005–2008. BMC Clin Pharmacol 2010; 10: 16. – ident: 2 – ident: 22 doi: 10.1161/CIRCULATIONAHA.122.061527 – ident: 8 doi: 10.1007/s11606-014-2993-8 – ident: 13 doi: 10.1016/j.amjcard.2021.08.013 – ident: 5 doi: 10.1161/CIRCULATIONAHA.115.018544 – ident: 20 doi: 10.1093/ageing/afu141 – ident: 21 doi: 10.1111/j.1447-0594.2011.00783.x – ident: 1 doi: 10.1186/1472-6904-10-16 – ident: 10 – ident: 14 – ident: 16 doi: 10.1161/CIRCULATIONAHA.106.685313 – ident: 12 doi: 10.1016/j.amjcard.2020.12.078 – ident: 3 doi: 10.1046/j.1525-1497.1998.00053.x – ident: 11 doi: 10.1016/j.amjcard.2020.12.076 – ident: 15 doi: 10.1161/CIRCULATIONAHA.110.009449 – ident: 19 doi: 10.1016/j.jamda.2017.12.013 – ident: 18 doi: 10.1007/s41999-019-00162-8 – ident: 9 doi: 10.1002/jcph.2106 – ident: 6 doi: 10.1136/bmj.i2868 – ident: 7 doi: 10.1111/jth.15692 – ident: 4 doi: 10.1001/jama.275.11.852 – ident: 17 doi: 10.1007/s11606-010-1518-3 – reference: 37914273 - Circ J. 2024 May 24;88(6):900-901. doi: 10.1253/circj.CJ-23-0720. |
| SSID | ssj0029059 |
| Score | 2.4134986 |
| Snippet | Background: Polypharmacy was reported to be associated with major bleeding in various populations. However, there are no data on polypharmacy and its... Polypharmacy was reported to be associated with major bleeding in various populations. However, there are no data on polypharmacy and its association with... |
| SourceID | proquest pubmed crossref jstage |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 888 |
| SubjectTerms | Aged Aged, 80 and over Bleeding Coronary stent Female Hemorrhage - chemically induced Humans Incidence Japan - epidemiology Male Middle Aged Percutaneous coronary intervention Percutaneous Coronary Intervention - adverse effects Polypharmacy Registries Risk Factors Treatment Outcome |
| Title | Polypharmacy and Bleeding Outcomes After Percutaneous Coronary Intervention |
| URI | https://www.jstage.jst.go.jp/article/circj/88/6/88_CJ-23-0558/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/37722886 https://www.proquest.com/docview/2866379651 |
| Volume | 88 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Circulation Journal, 2024/05/24, Vol.88(6), pp.888-899 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfKQIjLxOcoXwoSF1RlaxwncU5oRBujW7dJtFJvVuw4NFvXTG16GFf-cZ5jx81gQ4OLVbl23L73Yv-e_fx-CH3IBSVZDJ4qBzjikjj03Fjw1PUx90juZdSv2RuGx-HBmAwmwaTT-dmKWlpVfFv8uPFeyf9oFepAr-qW7D9o1j4UKuAz6BdK0DCUd9LxaTm7utS5p3Uapc8zvRj1TlYVDCiXvd2aA_xULsQKYKBUAa-JSlqgguW-tuId2yA1KRbCsHrZzBK3pZtQuHUAC64isuy1O5pwUDurpBcpWEW9MXtYWjWXi6KpHaXncjkt7O50Wi1XqSbVHqbLdFosbLdv06K80HTbUHtetLcuMFGn7vrGtJltfRK5hGJ9MCNvqDNTNKUtU2zPt1R_88c6gGsyDwH_-mw7GbhYxSjqFPHXU24fn7D98dERG-1NRvfQfRxF9Vn_l4mNE8Jxv2bcs7_LnHXDCDu_P_8atnlwBvD-u7zdc6kRzOgx2jSuh7Or7egJ6sj5U_RwaIIrnqHDtjk5YE5OY05OY05ObU5O25ycxpyctjk9R-P9vVFy4BquDVeEIalcDggGvOUI8F0_4DLvy0hkoQo1zQj2chwTnObE52FMQwA0WaAIzxT6BcjKvQz7L9DGvJzLl8hRWcl45kc8V3TmfZpySbM4Aj8kELGIZBftNFJiwiSiV3woM6YcUpArq-XKkgHDPlNy7aKPtselTsLyl7aftOBtS_N6mpaUslAV6x7rBiBhmFa66H2jMQZzrTpA0wJlmAI-j-Iw8LpoS6vSjuKDm4opDV_dofdr9Gj9OrxBG9ViJd8Ctq34u9r2fgHTLKki |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polypharmacy+and+Bleeding+Outcomes+After+Percutaneous+Coronary+Intervention&rft.jtitle=Circulation+journal+%3A+official+journal+of+the+Japanese+Circulation+Society&rft.au=Yamamoto%2C+Ko&rft.au=Morimoto%2C+Takeshi&rft.au=Natsuaki%2C+Masahiro&rft.au=Shiomi%2C+Hiroki&rft.date=2024-05-24&rft.issn=1347-4820&rft.eissn=1347-4820&rft.volume=88&rft.issue=6&rft.spage=888&rft_id=info:doi/10.1253%2Fcircj.CJ-23-0558&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-9843&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-9843&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-9843&client=summon |